Figure 2.
Effect of EZH2 inhibitor on lipid accumulation and adipogenic markers expression in human adipocytes. In vitro differentiated (6–12 days) primary human SQ preadipocytes were treated with EZH2 inhibitor (GSK126, 5 μm) or vehicle (DMSO). A and B, validation of GSK126 efficacy and selectivity via measurements of H3K27me3 (A) and H3K4me3 (B) protein levels. C, total intracellular protein concentration per well. D, representative appearance of cytoplasmic lipid droplets (ORO staining) 6 days post-adipogenic differentiation. Neutral lipid accumulation was quantified by spectrophotometry (n = 4). E, intracellular triglyceride content (n = 6). Shown are adipogenic marker (PPAR-γ and adiponectin) mRNA (F) and protein (G and H) levels 6 days post-adipogenic differentiation. *, p < 0.05; ***, p < 0.001; PA, preadipocytes. Error bars, S.E.